Kaia Health, a NYC-based digital therapeutics company focused on helping people manage chronic conditions, closed a $26m Series B funding round.
The round, which brought total funds raised to date to $50m, was led by Optum Ventures, Idinvest and capital300 with participation from existing investors Balderton Capital and Heartcore Capital, as well as Symphony Ventures.
The company will use the funds to drive growth of its core digital therapy solutions for people managing musculoskeletal (MSK) conditions, expand into new conditions such as COPD, continue to invest in its proprietary technology in clinical research, and expand its team to accelerate employer and health plan growth.
Founded in 2016 by Konstantin Mehl, President, Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain and COPD. Working with experts in various medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage their condition with digital alternatives from their home using devices they already own (i.e. smartphones and tablets). The company has enrolled more than 400,000 users to-date in their digital therapy program.